登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C25H28N6O
化学文摘社编号:
分子量:
428.53
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI key
YOSHYTLCDANDAN-UHFFFAOYSA-N
SMILES string
CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)-c4ccccc4-c5nnn[nH]5
InChI
1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
grade
pharmaceutical primary standard
API family
irbesartan
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... AGTR1(185)
正在寻找类似产品? 访问 产品对比指南
Application
Irbesartan USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Irbesartan Tablets
- Irbesartan and Hydrochlorothiazide Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
J C Gillis et al.
Drugs, 54(6), 885-902 (1998-01-09)
Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII. In patients with mild to moderate hypertension, once daily administration
Peter Bramlage et al.
Expert opinion on pharmacotherapy, 11(4), 521-535 (2009-12-25)
Guidelines recommend five antihypertensive drug classes, but which particular drug to choose is up to the treating physician. We aimed at an in-depth comparison of two frequently used angiotensin receptor blockers to provide evidence for this decision. Pharmacology of irbesartan
A J Palmer et al.
International journal of clinical practice, 61(10), 1626-1633 (2007-09-20)
The objective of the study was to determine the impact of irbesartan treatment on life expectancy (LE), costs and progression to end-stage renal disease (ESRD) in hypertensive type 2 diabetes patients. A peer-reviewed and published Markov model was used to
Giuseppe Derosa et al.
Current vascular pharmacology, 7(2), 120-136 (2009-04-10)
Blood pressure (BP) is one of the most important and common vascular risk factors but it is often poorly controlled. Inhibition of the renin-angiotensin-aldosterone system (RAAS) provides beneficial effects in hypertensives. The association of low-dosed diuretics in combination with RAAS
J M Flack
International journal of clinical practice, 61(12), 2093-2102 (2007-09-25)
Evidence-based guidelines for the management of hypertension are now well established. Studies have shown that more than 60% of patients with hypertension will require two or more drugs to achieve current treatment targets. Combination therapy is recommended as first-line treatment
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持